Together, drug-induced mutations in the SHH pathway were observed in four of six versus zero of 10 (66.67% vs. 0%, P = 0.008) SHH medulloblastomas in the SD-CSC versus SI-CSC subtypes, respectively. The gene discussed is SHH; the disease is medulloblastoma.